Workflow
特宝生物(688278) - 2023 Q1 - 季度财报
AMOYTOPAMOYTOP(SH:688278)2023-04-24 16:00

Financial Performance - The company's operating revenue for Q1 2023 was RMB 419,307,024.70, representing a year-on-year increase of 21.53%[4] - The net profit attributable to shareholders was RMB 84,173,127.64, reflecting a growth of 46.51% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 102,455,003.37, an increase of 35.62% year-on-year[4] - The basic earnings per share for the period was RMB 0.21, up by 50.00% from the previous year[4] - In Q1 2023, the company reported a net profit of ¥84,173,127.64, an increase of 46.5% compared to ¥57,452,423.77 in Q1 2022[20] - Operating profit for Q1 2023 was ¥118,990,858.09, up 33.5% from ¥89,006,711.83 in the same period last year[20] - Total revenue from sales and services received in Q1 2023 was ¥379,091,244.26, a rise from ¥368,702,244.57 in Q1 2022, reflecting a growth of 2.1%[21] - The company’s total comprehensive income for Q1 2023 was ¥84,173,127.64, an increase of 46.5% from ¥57,452,423.77 in Q1 2022[20] Research and Development - The total R&D investment amounted to RMB 70,109,028.96, which is a significant increase of 71.26% compared to the previous year[4] - The proportion of R&D investment to operating revenue was 16.72%, which increased by 4.85 percentage points year-on-year[5] - The company incurred research and development expenses of ¥37,712,423.75 in Q1 2023, significantly higher than ¥20,347,219.38 in Q1 2022, marking an increase of 85.7%[20] Cash Flow and Assets - The cash flow from operating activities was RMB 21,847,454.23, showing a decrease of 73.66% year-on-year[4] - The company’s cash flow from operating activities in Q1 2023 was ¥21,847,454.23, down 73.7% from ¥82,949,425.82 in Q1 2022[22] - The company's cash and cash equivalents increased to CNY 520,779,757.78 from CNY 301,240,536.26 at the end of 2022, representing a growth of 73%[14] - The company’s cash and cash equivalents at the end of Q1 2023 totaled ¥519,870,257.78, an increase from ¥491,191,572.08 at the end of Q1 2022[23] Assets and Liabilities - The total assets at the end of the reporting period were RMB 1,845,004,186.33, an increase of 4.32% from the end of the previous year[5] - As of March 31, 2023, total current assets were CNY 961,471,381.59, slightly up from CNY 955,610,910.65 at the end of 2022[14] - Non-current assets totaled CNY 883,532,804.74 as of March 31, 2023, compared to CNY 812,948,736.66 at the end of 2022, indicating an increase of 8.7%[15] - The company's total liabilities decreased to CNY 353,230,727.24 from CNY 360,959,315.86 at the end of 2022, a reduction of 2%[16] - The retained earnings increased to CNY 614,970,718.03 from CNY 530,797,590.39, reflecting a growth of 15.8%[17] Shareholder Information - The company reported a total of 5,888 common shareholders at the end of the reporting period[8]